I'm surprised how far MAB therapies already are, and how
fast they are progressing. They already have applications
besides cancers. Wouldn't this be an interesting solution or
complementary approach to LysoSENS? Especially, since
it's proven and working science.
Any reason it would be impractical to have B-cells (and maybe
phagocytes) gnaw more intensely and proactively at:
- amyloids and other junk (is there any comprehensive list of junk types?)
and less obviously, but perhaps possible:
- detected other misfolded proteins
- detected indigestible toxins in the bloodstream
- some death-resistant cell types with abnormal gene expression
- maybe even dead phagocytes and excess immune killer cells
- possibly even some crosslink types
As I understand SENS, its major hurdle should be transfection/delivery
of the solutions on a whole-body scale. If immune cells can already solve
a significant part, leading to some first rejuvenation results, transfection,
e.g. of lysosome-improving gene therapy, might first have to be limited to
bone marrow and some lymph nodes (still hard, but orders of magnitude
less hard than reaching most cells). True, perhaps vaccines may to the
same job (but constructing various custom antibodies, as this technology
gets better, might be more effective and faster).
(And for the nearer future, approaches including gene therapy for mtDNA expression
in the nucleus, could then primarily be done in still-intact stem cells designated for
already damaged organs (interventive, not preventive). Much better than nothing.)
MABs should be at least interesting to pursue it as complementary to LysoSENS
because, taking cancer as example, immune cells can very well digest all cancer
cells I could think of, but the problem arises when they don't (or not sufficiently
or early enough). Also, MAB shows more/broader promise than vaccines for cancer.
And amyloids targeting MABs, if feasible, sounds like something that big pharma
companies might easily agree to research, or might already have in their pipelines.
[ Addition: I see that the 'fun' of this approach would be ensuring 100% to avoid
antibodies that lead to attacks on: melanosomes, tPA, calcitonin and some functional
amyloid precursor proteins. However, engineered antibodies may be even more
specific and thus less risky than any vaccination approaches in this case. ]
